Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 93-100

  Álvarez Lerma, Francisco ^a   Allepuz Palau, A ^b   Gracia, M P ^a   Angeles Leon M ^c   Navarro, A ^d   Sanchez Ruiz H ^e   Iruretagoyena, J R ^f   Luque Gomez P ^g  

^a HOSPITAL DEL MAR   (Spain)

^b Catalan Agency for Health Technology Assessment and Research   (Spain)

^c HOSPITAL GENERAL DE CATALUNYA   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Cyclodextrin sodium; Intravenous route; Mortality; Renal damage; Renal failure; Voriconazole

Indexed keywords

CREATININE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MYCOSIS; NEPHROTOXICITY;

EID: 41149159802     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.93     Document Type: Article

References (9)

1. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs 2001; 37:135-148.
2. Theuretzbacher U, Ihle F, Derendorrf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.
3. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56:10-16.
4. FDA Antiviral Drugs Advisory Committee - Briefing Document for Voriconazole (Oral and Intravenous Formulations). http://www.fda.oov/ohrms/ dockets/ac/01/ briefing/3792b2_01_Pfizer.pdf
5. Von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clinical Pharmacology 2006; 6:6. http://www.biomedcentral.com/1472-6904/6/6.
6. Álvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez- Borregán JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005;17:417-427.
7. Gould S, Scott RC. 2-Hidroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005; 43:1451-9.
8. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 2000; 30:236-237.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P and the ADQI workgroup. Acute renal failure-definitions, outcome mesures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8: R204-R212 (DOI 10.1186/ cc2872). URL: http://ccforum.com/content/ 8/4/R204